Your CBD Store® Opens New Location In Alexandria, VA

ALEXANDRIA, Va.–(BUSINESS WIRE)–National CBD retailer Your CBD Store® announced today that the company has opened a new store in Alexandria, Virginia. In less than two years, Your CBD Store® retailers have created the world’s largest brick and mortar CBD retailer, with over 600 locations in 40 states. Founded with an emphasis on education and community, Your CBD Store® has grown by educating customers about misconceptions regarding its hemp derived products.

“Everything we do is focused on improving the lives of our customers, we are a high-quality learning environment where customers can try products and leave knowing what is in their CBD product,” said Shells Karle, store owner of Your CBD Store Alexandria. “We are not just another retail chain. We are a community of store owners who truly care and are educating CBD consumers around the nation.”

Cannabidiol, better known as CBD, may be one of the most broadly therapeutic plant extracts of our time. It comes from the cannabis sativa plant, which is not the same plant that the USDA has defined as marijuana. Rather, company products come from “Industrial Hemp.” This distinction means the extract is chemically unique, high in CBD and completely legal. It also accounts for its wide range of medical applications. Along with its lengthy list of therapeutic properties, these products come with the backing of the medical community, the World Health Organization, the nursing community, and the veterinary community.

Since its creation, Your CBD Store® has received thousands of 5-star reviews from customers on Google and Facebook. With a focus on quality, Your CBD Store® has helped drive legislation in Florida and other states toward transparency and product testing. Third party lab reports as well as lot and batch numbers can be found on every company product.

Your CBD Store® offers a variety of CBD infused products that don’t require a prescription or medical card to buy. Company stores only sell products manufactured by SunMed, which uses a special CO2 extraction process to eliminate the need for chemical solvents to produce a high-quality, full-spectrum CBD. The CBD is then processed again to remove all traces of THC for the company’s zero-THC products.

The new Your CBD Store of Alexandria is now open and located at 301 S Washington St., Suite B, Alexandria, VA 22314.

ABOUT Your CBD Store®

Your CBD Store®, is the nation’s fastest growing retail channel for CBD users with over 600 locations. By 2020, it is expected there will be over 1,000 stores across the country. Rachael Quinn, Your CBD Store® founder, shares her desire to inspire others through the use of natural, hemp-derived products. Each Your CBD Store® offers a comfortable and inviting environment where guests can learn about CBD, try samples and feel empowered to make a confident choice on the best cannabinoid formulation option for them. Their organic growth and dedication to bettering the community through transparent product information from high-quality premium product lines backed by third party laboratory testing make SunMed™ CBD products a refreshing new standard in the CBD space. For more information about the company or to find out how to start a store, visit the company online at


Carolynn Smith-Jones

(917) 708-1983

Applied DNA Receives Kosher Certification from Orthodox Union for Qualifying Products

Products within the SigNature® and CertainT® Brand Certified in Strict Compliance with OU Standards as Ingredients for Dietary Supplements, Pharmaceuticals and Food Products

STONY BROOK, N.Y.–(BUSINESS WIRE)–$apdn #anticounterfeitingApplied DNA Sciences, Inc. (“Applied DNA”, the “Company”, NASDAQ: APDN), announced receipt of certification from the Orthodox Union (OU®) for products within the SigNature and CertainT line following a thorough evaluation of the Company’s products and manufacturing processes. The Pareve kosher designation will first be used for the Nutrition21 Nitrosigine® sports supplement product recently announced. The Company’s products and services, used by its customers to manage traceability and authenticity in the name of brand assurance, are also suitable for related markets such as food and pharmaceuticals.

The OU (Orthodox Union) Kosher is the world’s largest and most widely recognized international kosher certification agency, certifying over 800,000 products produced in more than 9,011 plants located in 104 countries around the world. Over $150 billion of kosher certified products are consumed annually, with the OU kosher symbol appearing on close to 70% of America’s kosher certified foods.

“As we grow our presence in food, pharmaceutical and dietary supplements markets, we are pleased to be supportive of the business imperatives critical to meet market requirements that maximize adoption. We are proud to have the OU certification on our qualifying products. OU maintains strict guidelines for certification and ongoing manufacturing, marketing and distribution of products, making Applied DNA’s mission for enabling our customers a platform for proof of authenticity and traceability nicely complementary for OU-certified products,” said Dr. James Hayward, president and CEO, Applied DNA.

The Company’s qualifying CertainT and SigNature molecular tags enable companies and their supply chains to designate a unique molecular identity to products with meaning specific to the tagged material: for example, geographic facility location, brand, product line or date of manufacture. This tag can be blended into ingredients and packaging inks and varnishes in the pharmaceutical, nutraceutical, and dietary supplements industry. The tag enables its carrier to be verified for authenticity and blending detection, either at the customer or in the Applied DNA laboratory, depending on application requirements.

“Applied DNA Sciences is leading the way in supply chain authentication,” commented Rabbi Menachem Genack, CEO, OU Kosher, “and we are excited to partner with them as they expand into the market of dietary supplements, food ingredients and nutraceuticals. In turn,” he observed, “their molecular tag offers our supervision program an additional instrument for validating the integrity of our certified products.”

About Applied DNA Sciences

Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and pre-clinical nucleic acid-based therapeutic drug candidates.

Applied DNA makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.

Visit for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

Common stock listed on NASDAQ under the symbol APDN.

Forward-Looking Statements

The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to our ability to successfully enter into commercial contracts for the implementation of our CertainT® platform, the possibility of failure to make timely payment on its outstanding secured convertible notes and resulting enforcement by noteholders of remedies on collateral which includes substantially all of Applied DNA’s assets, the Company’s history of net losses, limited financial resources, limited market acceptance and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 12, 2019 and our subsequent quarterly report on Form 10-Q filed on February 6, 2020, and other reports we file with the SEC, which are available at Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.


investor contact: Sanjay M. Hurry, LHA Investor Relations, 212-838-3777,
program contacts
: Judy Murrah, Chief Information Officer, 631-240-8819,
twitter: @APDN


Brightmark to Expand Western New York Dairy Biogas Project

Project upgrading six Buffalo-area anaerobic digesters from electric to renewable natural gas output

SAN FRANCISCO–(BUSINESS WIRE)–#RNG–Brightmark, a San Francisco-based waste to energy development company, announced today that it has expanded its Western New York dairy biogas project to partner with six total farms throughout the region. Including two new farms, the Yellowjacket project will extract methane from 265,000 gallons of dairy manure per day and convert it into renewable natural gas (RNG) and other useful products.

Farms participating in the Yellowjacket renewable natural gas project include:

  • Boxler Dairy Farm – Varysburg, Wyoming County
  • Lamb Lakeshore Dairy – Wilson, Niagara County
  • Lamb Farms – Oakfield, Genesee County
  • Lawnhurst – Stanley, Ontario County
  • Swiss Valley Farms – Warsaw, Wyoming County
  • Zuber Farms – Byron, Genesee County

After the planned installation of gas upgrade equipment across all of the farms is complete in early 2021, the project is anticipated to produce about 305,000 MMBtu of renewable natural gas each year, making this Brightmark’s largest RNG project to date. The company has partnered on biogas projects with 17 dairy farms in five states over the past two years. Once all of these projects are operational, Brightmark’s RNG projects will generate enough renewable natural gas to drive an average passenger car 7,747,000 miles.

“We’re excited to expand our footprint in Western New York through the expansion of the Yellowjacket RNG project,” said Brightmark CEO Bob Powell. “We’re proud to partner with farmers who are on the leading edge of sustainability so that they can improve their bottom lines while being good stewards of their local environment.”

Previously, the anaerobic digesters on these farms produced electricity that was used both onsite by the farms and transmitted to the local electric grid. However, some of the digesters are more than 10 years old, and they had begun to cost more to maintain and operate than they generated in value. Brightmark’s investments will include upgrading each digester to new technology capable of cleaning the methane gas and converting it into high quality RNG for use in heating or transportation. The gas is expected to be injected into a local interstate gas pipeline.

After refurbishment work is completed on the systems, participating farmers expect to see drastically greater returns on their digesters, while further minimizing the local environmental impacts of the manure generated by their herds.

“We’re really committed to protecting the environment and doing what’s best for the local community,” said Don Jensen, owner of Lawnhurst Farms. “We are excited to have the opportunity to partner with Brightmark to convert from generating electricity to producing RNG. This process will greatly reduce operational costs and with this technology increase the return on our investment.”

Anaerobic digestion of dairy cow manure has been shown to significantly reduce local pollution and greenhouse gas emissions. The process retains most of the nitrogen and phosphorous from manure and uses these nutrients to create balanced biofertilizers that help grow local crops. Anaerobic digestion systems can prevent significant quantities of methane, a potent greenhouse gas, from being released into the atmosphere. This project will reduce the net greenhouse gas emissions from the manure processed at this facility at a rate of 117,783 metric tons per year, which is equivalent to planting 152,824 acres of forest each yeari.

The New York State Energy Research and Development Authority (NYSERDA) is providing initial project planning funding and projects may be eligible for additional funding to implement upgrades to the digesters.

Brightmark is actively seeking other dairy farmers, wastewater treatment plant operators, and feedstock suppliers with an interest in collaborating on biogas projects throughout the United States.


Brightmark develops, owns and operates waste and energy projects. Brightmark employs technology solutions including combined heat and power, biogas, and waste to energy that are specifically tailored based on customer needs. Brightmark Energy’s mission is to create significant long-term value and a positive global impact by delivering waste and energy solutions. Learn more at

i Calculated via


Jamie Nolan

PPD Announces Fourth Quarter and Full Year 2019 Earnings Release Date and Conference Call

WILMINGTON, N.C.–(BUSINESS WIRE)–PPD, Inc. (Nasdaq:PPD), a leading global contract research organization, today announced it will release its fourth quarter and full year 2019 results and issue full year 2020 guidance after market close on Wednesday, March 4, 2020. The earnings release and accompanying financial information will be available on the investors section of PPD’s website at The release will be followed by a conference call on Thursday, March 5, 2020, at 8:30 a.m. (U.S. Eastern Time). The conference call can be accessed live by phone by dialing +1 877 407 0784, or for international callers, +1 201 689 8560.

Investors and other interested parties also may listen to a live webcast of the conference call by logging onto the presentations page of the investors section of PPD’s website at A replay of the webcast will be available shortly after the call has concluded. In addition, an audio replay will be available after the call and can be accessed by dialing +1 844 512 2921, or for international callers, +1 412 317 6671. The passcode for the live conference call and the replay is 13698656. The audio replay will be available until Thursday, March 19, 2020.

About PPD

PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our customers include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and approximately 23,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help customers bend the cost and time curve of drug development and optimize value in delivering life-changing therapies to improve health. For more information, visit



Ned Glascock

+1 910 558 8760


+1 910 558 2899

Verana Health Appoints Veteran Cardiologist and Clinical Researcher, Dr. Matthew Roe, as Chief Medical Officer

SAN FRANCISCO–(BUSINESS WIRE)–Verana Health today announced the appointment of Matthew Roe, MD, MHS, as Chief Medical Officer. A cardiologist and clinical researcher, Dr. Roe joins Verana Health after spending over two decades at the Duke University School of Medicine and the Duke Clinical Research Institute (DCRI), the world’s largest academic clinical research organization. At Duke, he focused on research initiatives leveraging real-world data and patient engagement.

“Dr. Roe is an acclaimed physician-scientist with over two decades of experience focused on the intersection of patient care and real-world data; a complete alignment with the clinical efforts of Verana Health,” said Miki Kapoor, CEO of Verana Health. “As a physician and researcher, Matt’s focus has been on developing and testing different ways technology and real-world data can be combined to transform clinical research. We are thrilled to bring his extraordinary knowledge to our team and further accelerate the use and applications of real-world data in scientifically rigorous approaches to generate real-world evidence for the healthcare ecosystem.”

As Chief Medical Officer, Dr. Roe will lead Verana’s medical and data science teams working to ensure the clinical validity and scientific integrity of its research. He will also work closely with regulatory agencies and the medical/scientific community, focusing on data quality while also expanding the applications of regulatory-grade data that are being developed from Verana’s data partnerships.

“Verana has built trusted relationships with some of the largest medical associations in the country,” added Dr. Roe. “These collaborations put us in a unique position to connect real-world data across sources, types, time, and scale to create a more complete view of human health and the patient journey. I’m excited to bring my experience to this incredible team to further realize the ways real-world data can enable the clinician-patient relationship and improve the health of patients across diverse medical conditions.”

Dr. Roe was previously a co-principal investigator for the ADAPTABLE trial — highlighted by the FDA as a successful example of a real-world data study in their framework for real-world evidence guidelines. He also led several observational registries with a focus on the treatment and outcomes of patients with cardiovascular disease. At the DCRI — known for its trailblazing approaches in the real-world evidence space — Dr. Roe served as Senior Investigator as well as the Director of the organization’s Clinical Research Fellowship and “Think Tank” series between 2010 and 2019.

Dr. Roe received his MD and MHS degrees from Duke University School of Medicine in 1993 and 2001, respectively. He completed an Internal Medicine residency at Duke University Medical Center in 1996 and a Cardiovascular Fellowship at the Cleveland Clinic Foundation in 1999.

About Verana Health

Verana Health is a technology company assembling the largest clinical databases in medicine. Verana Health utilizes this real-world data to derive clinical and business insights for physicians and life science companies through its regulatory-grade data platform. By activating this vast amount of data, Verana Health can learn from the collective experience of millions of individual patients to empower physicians and accelerate research for patients. Learn more at


David Cirilli at Untitled Partners: or 646.727.0063

North America Apheresis Equipment Market Analysis & Forecasts to 2027 –

DUBLIN–(BUSINESS WIRE)–The “North America Apheresis Equipment Market to 2027 – Regional Analysis and Forecasts By Product; Technology; Procedure; Therapeutic Area; End User, and Country” report has been added to’s offering.

The North America apheresis equipment market is expected to reach US$ 1,387.38 Mn in 2027 from US$ 755.36 Mn in 2018. The market is estimated to grow with a CAGR of 7.3% from 2019-2027.

The growth of the apheresis equipment market is primarily attributed to the increasing elderly population and the increasing incidence of hematologic diseases. However, complications associated with apheresis are likely to have a negative impact on market growth. On the other hand, growing medical tourism in Mexico is likely to have a positive impact on the growth of the North America apheresis equipment market in the coming years.

Apheresis is a process in which blood is temporarily removed from the donor’s body and separated into various components such as plasma, platelets, red blood cells as well as white blood cells. It is done by centrifugation or membrane separation process. Blood diseases affect one or more parts of the body as well as total health. There are various blood diseases caused by certain genes. Some of the common blood diseases include anemia, hemophilia, von Willebrand disease (VWD), blood cancers such as myeloma, leukemia-lymphoma and others. The rising number of these diseases demands the need for a blood transfusion which is expected to increase the requirement of apheresis equipment, thereby bolstering the growth of the market.

Anemia is known to be the common blood disorder, and according to the National Heart, Lung, and Blood Institute, it affects more than 3 million Americans. For instance, according to the Centers for Diseases Control and Prevention (2017), approx. 5,382 deaths were estimated due to the anemia incidences in the U.S. Two of the most common types of apheresis used for the removal of a harmful substances from blood are cytapheresis and plasma exchange. Plasma exchange is used to treat disorders such as myasthenia gravis, thrombotic thrombocytopenic purpura, multiple sclerosis and others. Cytapheresis is a process that removes an excess number of blood cells and is used in the treatment of leukemia, polycythemia and thrombocythemia. Thus, the rising incidence of hematologic diseases is expected to foster the growth of the apheresis equipment market in the region over the coming years.

Reasons to Buy

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the North America apheresis equipment market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the North America apheresis equipment market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth regional market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

Key Topics Covered:

1. Introduction

1.1 Scope of the Study

1.2 Research Report Guidance

2. North America Apheresis Equipment Market – Key Takeaways

3. North America Apheresis Equipment Market – Market Landscape

3.1 Overview

3.2 Market Segmentation

3.3 PEST Analysis

4. North America Apheresis Equipment Market – Key Market Dynamics

4.1 Key Market Drivers

4.2 Key Market Restraints

4.3 Key Market Opportunities

4.4 Future Trends

4.5 Impact Analysis

5. Apheresis Equipment Market – North America Analysis

5.1 North America Apheresis Equipment Market Revenue Forecasts And Analysis

5.2 Market Positioning

6. North America Apheresis Equipment Market Analysis – By Product

6.1 Overview

6.2 North America Apheresis Equipment Market By Product, 2018 & 2027 (%)

6.3 North America Apheresis Equipment Market Revenue And Forecasts to 2027, By Product (US$ Mn)

6.4 Disposable Apheresis Kits Market

6.5 Apheresis Machine Market

7. North America Apheresis Equipment Market Analysis – By Technology

7.1 Overview

7.2 North America Apheresis Equipment Market, By Technology, 2018 & 2027 (%)

7.3 North America Apheresis Equipment Market Revenue And Forecasts to 2027, By Technology (US$ Mn)

7.4 Centrifugation Market

7.5 Membrane Separation Market

8. North America Apheresis Equipment Market Analysis – By Procedure

8.1 Overview

8.2 North America Apheresis Equipment Market, By Procedure, 2018 & 2027 (%)

8.3 North America Apheresis Equipment Market Revenue And Forecasts to 2027, By Procedure (US$ Mn)

8.4 Plasmapheresis Market

8.5 Photopheresis Market

8.6 Erythrocytapheresis Market

8.7 Leukapheresis Market

8.8 Plateletpheresis Market

8.9 LDL-Apheresis Market

9. North America Apheresis Equipment Market Analysis – By Therapeutic Area

9.1 Overview

9.2 North America Apheresis Equipment Market, By Therapeutic Area, 2018 & 2027 (%)

9.3 North America Apheresis Equipment Market Revenue And Forecasts to 2027, By Therapeutic Area (US$ Mn)

9.4 Haematology Market

9.5 Renal Diseases Market

9.6 Neurology Market

9.7 Other Applications Market

10. North America Apheresis Equipment Market Analysis – By End User

10.1 Overview

10.2 North America Apheresis Equipment Market, By End User, 2018 & 2027 (%)

10.3 North America Apheresis Equipment Market Revenue And Forecasts to 2027, By End User (US$ Mn)

10.4 Hospitals & Clinics

10.5 Blood Banks/ Blood Donation Centers

10.6 Ambulatory Surgical Centers

11. North America Apheresis Equipment Market Revenue and Forecasts To 2027

11.1 Overview

12. Apheresis Equipment Market – Industry Landscape

12.1 Overview

13. Apheresis Equipment Market-Key Company Profiles

13.1 Medica S.p.A.

13.2 Fresenius Medical Care AG & Co. KGaA

13.3 Asahi Kasei Corporation

13.4 Terumo Corporation

13.5 B. Braun Melsungen AG

13.6 Haemonetics Corporation

13.7 Hemacare Corporation

13.8 Kaneka Medix Corp

13.9 Kawasumi laboratories. Inc.

13.10 medicap clinic GmbH

For more information about this report visit


Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

IVERIC bio to Report Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on Thursday, February 27, 2020

NEW YORK–(BUSINESS WIRE)–IVERIC bio, Inc. (Nasdaq: ISEE) today announced that it will report its fourth quarter and full year 2019 financial and operating results on Thursday, February 27, 2020. Following the announcement, the IVERIC bio management team will host a live conference call and webcast at 8:00 a.m. Eastern Time to discuss the Company’s financial results and provide a general business update.

To participate in this conference call, dial 800-458-4121 (USA) or 323-794-2598 (International), passcode 6010573. A live, listen-only audio webcast of the conference call can be accessed on the Investors section of the IVERIC bio website at A replay will be available approximately two hours following the live call for two weeks. The replay number is 888-203-1112 (USA Toll Free), passcode 6010573.

About IVERIC bio

IVERIC bio is a biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. Vision is Our Mission. For more information on the Company please visit

Forward-looking Statements

Any statements in this press release about IVERIC bio’s future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Any forward-looking statements represent IVERIC bio’s views only as of the date of this press release. IVERIC bio anticipates that subsequent events and developments will cause its views to change. While IVERIC bio may elect to update these forward-looking statements at some point in the future, IVERIC bio specifically disclaims any obligation to do so.



Investor Contact:

Kathy Galante, 212-845-8231

Vice President, Investor Relations and Corporate Communications


Media Contact:

Alex Van Rees, 973-442-1555 ext. 111

scPharmaceuticals Inc. to Present at the 9th Annual SVB Leerink Global Healthcare Conference

BURLINGTON, Mass.–(BUSINESS WIRE)–$SCPH #FUROSCIX–scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs, today announced that John Tucker, president and chief executive officer, will present at the 9th Annual SVB Leerink Global Healthcare Conference at 10:00 a.m. ET on Tuesday, February 25, 2020, at the Lotte New York Palace Hotel in New York, NY.

Investors interested in arranging a meeting with the Company’s management during this conference should contact the conference coordinator.

About scPharmaceuticals

scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that are designed to reduce healthcare costs and improve health outcomes. The Company develops, internally and through strategic partnerships, innovative products and solutions that aim to expand and advance the outpatient care of select acute conditions. The Company’s lead programs focus on the subcutaneous, self-administration of IV-strength treatments in heart failure and infectious disease. scPharmaceuticals is headquartered in Burlington, MA. For more information, please visit


Katherine Taudvin

scPharmaceuticals Inc., 781-301-6706

Christopher F. Brinzey

Westwicke, an ICR Company, 339-970-2843

Eureka Therapeutics to Present at 6th Annual Immuno-Oncology 360° Conference

EMERYVILLE, Calif.–(BUSINESS WIRE)–Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced that President and CEO Dr. Cheng Liu will be presenting at the 6th Annual Immuno-Oncology 360° Conference (IO360°) in New York on February 27, 2020.

Dr. Liu will be presenting the use of Eureka’s novel antibody-TCR receptor (ARTEMIS® T cell) that has been engineered with a proprietary human TCR-mimic antibody to target an alpha fetoprotein (AFP)-peptide/HLA-A2 complex on HCC cancer cells.

Presentation Details

Title: Innovation Hour: New Scientific Frontiers in Cell Therapies for Solid Tumors

Speaker: Dr. Cheng Liu, President and CEO

Date: Thursday, February 27, 2020

Program: Cell & Gene Therapy Day, Track B

Time: 10:40 – 11:40 a.m. EST

About Eureka Therapeutics, Inc.

Eureka Therapeutics, Inc. is a privately held clinical stage biotechnology company focused on developing novel T cell therapies to treat cancers. Its core technology centers around its proprietary ARTEMIS® AbTCR T cell receptor platform and E-ALPHA® antibody discovery platform for the discovery and development of potentially safer and more effective T cell therapies for the treatment of multiple solid and hematologic tumors. ET140202, the Company’s lead asset, is currently in a Phase I/II US multicenter clinical trial in patients with advanced hepatocellular carcinoma (HCC).

Eureka Therapeutics, Inc. is headquartered in the San Francisco Bay Area. For more information on Eureka, please visit


Eureka Therapeutics, Inc.

Natalie Liu

Investor Relations


KKH Advisors

Kimberly Ha


Lineage Cell Therapeutics to Present at Biocom’s 10th Annual Global Life Sciences Partnering Conference

CARLSBAD, Calif.–(BUSINESS WIRE)–$LCTX #AMDLineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Brian M. Culley, Chief Executive Officer, will be presenting at Biocom’s 10th Annual Global Life Sciences Partnering Conference on February 27, 2020 at 2:30pm Pacific Time at the Lodge at Torrey Pines, La Jolla, CA.

In its 10th year, the 2020 Biocom Global Life Science Partnering Conference is an exclusive partnering forum that provides senior executives, bankers, venture capitalists, and business development professionals from the leading pharmaceutical and biotech companies to network and do business with one another from around the globe. This annual biopharma partnering conference brings together leading deal makers and emerging biotechs from around the world, while providing a local San Diego venue to showcase the impressive accomplishments and progress taking place in one of the top biotech hubs in the world. Interested parties may follow @BiocomCA on Twitter for the latest conference updates.

About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally-differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed either to replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase I/IIa development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase I/IIa development for the treatment of acute spinal cord injuries; and (iii) VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells currently in Phase I development for the treatment of non-small cell lung cancer. Lineage is also evaluating potential partnership opportunities for Renevia®, a facial aesthetics product that was recently granted a Conformité Européenne (CE) Mark. For more information, please visit or follow the Company on Twitter @LineageCell.


Lineage Cell Therapeutics, Inc. IR
Ioana C. Hone


(442) 287-8963

Solebury Trout IR
Gitanjali Jain Ogawa


(646) 378-2949